The following post was inspired by an interesting video of one of the AstraZeneca Seminars that was held at University of Toronto, Mississauga, in collaboration with AstraZeneca and UTM Biotech. The video is titled “Abbott Inc.’s Bioabsorbable Stent: Opportunities for Market Dominance“.
This video discusses some treatment options for cardiovascular diseases. These treatments are divided into several categories based on anatomy of the patient, and severity of the illness. Some of the treatments that were mentioned in this video are as follows:
1) Life Style Changes
2) Medications
3) Angioplasty (PCI: Percutaneous Coronary Intervention).
Angioplasty refers to unblocking of blood vessels by enlarging or re-opening them; hence, it is far less invasive than surgery. See this article for more detail on this medical procedure.
a. Stenting
b. Baloon Angioplasty (Video 1, Reading)
4) Surgery (CABG: Cardiovascular Artery Bypass Graft) (Video 1, Video 2, Video 3, Reading)
This article talks about differences between Bare Metals and Drug Eluting Stents. Watch this video too. Just thought to add it here since it relates.
The video discusses how Bioabsorbable stents decrease side effects remarkably.
As one may see from this figure BVS eliminates side effects such as TLR (target lesion revascularization) and Thrombosis. It diminishes MACE (major adverse cardiac events) but increases incidences of Restenosis.
Abbott is conducting further studies to diminish the chances of getting restenosis from bioabsorbable stent therapy. Here are further readings.
Reading 1: Miracle Stent, a Future without Restenosis.
Reading 2: Bioabsorbable Stents Show Promise
Reading 3: Abbott moves forward with Bioabsorbable Stents
Enjoy your readings!
Later Days….
careerxpert001
